Keywords: Basilea, Janssen-Cilag, Zevetera, Swiss sales, Johnson & Johnson, Isavuconazole, Astellas, Antifungals

Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas

Article | 13 September 2010

Print This

Switzerland-based Basilea (BSLN: S) says that its partner Janssen-Cilag AG, a unit of US health care giant Johnson & Johnson ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in